26 January 2023 - As the Government moves toward expanding insurance coverage for atopic dermatitis from adult to children and adolescent patients, negotiation will likely speed up to give benefits to injections and pills.

For example, Sanofi is bargaining with the National Health Insurance Service to determine the price of Dupixent (dupilumab) after it won recognition for the drug’s efficacy for children and adolescents with skin trouble two weeks ago.

Read Korea Biomedical Review article